Celcuity, Inc. (CELC)
60.46
-3.91
(-6.07%)
USD |
NASDAQ |
Nov 16, 16:00
60.46
0.00 (0.00%)
After-Hours: 18:57
Celcuity Net Income (Quarterly) : -73.34M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -73.34M |
| June 30, 2026 | -78.86M |
| March 31, 2026 | -52.84M |
| December 31, 2025 | -50.97M |
| September 30, 2025 | -43.80M |
| June 30, 2025 | -45.27M |
| March 31, 2025 | -37.00M |
| December 31, 2024 | -36.65M |
| September 30, 2024 | -29.79M |
| June 30, 2024 | -23.72M |
| March 31, 2024 | -21.61M |
| December 31, 2023 | -18.85M |
| September 30, 2023 | -18.40M |
| June 30, 2023 | -14.59M |
| March 31, 2023 | -11.94M |
| December 31, 2022 | -11.58M |
| September 30, 2022 | -10.89M |
| June 30, 2022 | -9.960M |
| March 31, 2022 | -7.934M |
| December 31, 2021 | -6.754M |
| September 30, 2021 | -6.027M |
| Date | Value |
|---|---|
| June 30, 2021 | -14.03M |
| March 31, 2021 | -2.792M |
| December 31, 2020 | -2.551M |
| September 30, 2020 | -2.474M |
| June 30, 2020 | -2.202M |
| March 31, 2020 | -2.247M |
| December 31, 2019 | -1.809M |
| September 30, 2019 | -1.984M |
| June 30, 2019 | -1.720M |
| March 31, 2019 | -1.846M |
| December 31, 2018 | -1.825M |
| September 30, 2018 | -1.871M |
| June 30, 2018 | -1.816M |
| March 31, 2018 | -1.968M |
| December 31, 2017 | -1.724M |
| September 30, 2017 | -1.764M |
| June 30, 2017 | -1.776M |
| March 31, 2017 | -0.9874M |
| June 30, 2016 | -0.82M |
| March 31, 2016 | -0.7195M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Beam Therapeutics, Inc. | -134.40M |
| Vera Therapeutics, Inc. | -93.71M |
| Tango Therapeutics, Inc. | -68.39M |
| Sarepta Therapeutics, Inc. | -28.46M |
| Allogene Therapeutics, Inc. | -50.37M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 73.34M |
| EPS Diluted (Quarterly) | -1.330 |
| Enterprise Value | 3.274B |
| Earnings Yield | -7.79% |
| Normalized Earnings Yield | -7.546 |